We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03489278
Previous Study | Return to List | Next Study

Clinical Procedures to Support Research in ALS (CAPTURE-ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03489278
Recruitment Status : Recruiting
First Posted : April 5, 2018
Last Update Posted : March 22, 2023
Sponsor:
Collaborators:
Muscular Dystrophy Association
National Institute of Neurological Disorders and Stroke (NINDS)
National Center for Advancing Translational Sciences (NCATS)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Michael Benatar, University of Miami

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.

Condition or disease
Amyotrophic Lateral Sclerosis ALS-Frontotemporal Dementia Primary Lateral Sclerosis Progressive Muscular Atrophy

Detailed Description:
The study will consent patients with ALS or related disorders that are receiving care at a clinical center in the CReATe consortium that uses Epic as its electronic health record (EHR) system. The study aims to systematically gather a clinical dataset through the EHR using a standardized approach to characterize the natural history of ALS and related diseases.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Procedures to Support Research in ALS (CAPTURE-ALS)
Actual Study Start Date : February 15, 2018
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Affected
Affected with ALS or a related disorder.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Using the ALS Toolkit for collecting and using electronic health record data for research purposes [ Time Frame: 12 months ]

Biospecimen Retention:   Samples With DNA
Optional: Provide blood for a DNA sample during a clinic visit. Participants can choose to allow collection of information from their medical record, but choose not to give a blood sample for testing.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Affected patients receiving care at a clinical center that uses Epic as EHR.
Criteria

Inclusion Criteria:

  • Diagnosis of ALS or a related disorder (e.g. primary lateral sclerosis, progressive muscular atrophy).
  • Receiving care at a clinical center that uses Epic as its EHR.
  • Able and willing to provide informed consent (or informed consent obtainable from a designated proxy).

Exclusion Criteria:

  • Inability to understand English and/or Spanish
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03489278


Contacts
Layout table for location contacts
Contact: Michael Benatar, MBChB, MS, DPhil 1-844-837-1031 projectcreate@miami.edu
Contact: Anne-Laure Grignon 1-844-837-1031 projectcreate@miami.edu

Locations
Layout table for location information
United States, California
University of California, Irvine Recruiting
Irvine, California, United States, 92868
Contact: Mercedes Herrera    714-509-2665    mercedh1@hs.uci.edu   
Principal Investigator: Namita Goyal, MD         
Stanford University Recruiting
Palo Alto, California, United States, 94304
Contact: Rabia Farooquee    650-709-8735    rfarooquee@stanford.edu   
Principal Investigator: Yuen T So, MD         
California Pacific Medical Center Recruiting
San Francisco, California, United States, 94115
Contact: Chow Saephanh    415-600-3935    SaephaC@cpmcri.org   
Principal Investigator: Jonathan Katz, MD         
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Jessica Hernandez    305-243-2345    jph93@miami.edu   
Principal Investigator: Michael Benatar, MBChB, MS, DPhil         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66205
Contact: Collin Gerringer    913-574-0008    cgerringer@kumc.edu   
Principal Investigator: Jeffrey Statland, MD         
United States, Minnesota
Hennepin County Medical Center Recruiting
Minneapolis, Minnesota, United States, 55404
Contact: Daphne Fruchtman    612-873-2607    DFruchtman@hhrinstitute.org   
Principal Investigator: Samuel Maiser, MD         
United States, New York
Columbia University Recruiting
New York, New York, United States, 10032
Contact: Ben Hoover    646-574-7399    bnh2119@cumc.columbia.edu   
Principal Investigator: Matthew Harms, MD         
United States, North Carolina
Wake Forest University Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Lauren Richmond    336-716-9632    lprichmo@wakehealth.edu   
Principal Investigator: James Caress, MD         
United States, Oregon
Providence Health & Services Recruiting
Portland, Oregon, United States, 97213
Contact: Tyler Regan    503-215-2333    tyler.regan@providence.org   
Principal Investigator: Nicholas Olney, MD         
United States, Texas
University of Texas San Antonio Health Science Center Recruiting
San Antonio, Texas, United States, 78229
Contact: Samantha Lewis    210-450-0524    lewiss11@uthscsa.edu   
Principal Investigator: Carlayne Jackson, MD         
Sponsors and Collaborators
University of Miami
Muscular Dystrophy Association
National Institute of Neurological Disorders and Stroke (NINDS)
National Center for Advancing Translational Sciences (NCATS)
National Institutes of Health (NIH)
Investigators
Layout table for investigator information
Principal Investigator: Michael Benatar, MBChB, MS, DPhil University of Miami
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Michael Benatar, Chief, Neuromuscular Division, University of Miami
ClinicalTrials.gov Identifier: NCT03489278    
Other Study ID Numbers: 20170785
U54NS092091 ( U.S. NIH Grant/Contract )
First Posted: April 5, 2018    Key Record Dates
Last Update Posted: March 22, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Muscular Atrophy
Frontotemporal Dementia
Aphasia, Primary Progressive
Pick Disease of the Brain
Muscular Atrophy, Spinal
Sclerosis
Pathologic Processes
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
 Atrophy
Pathological Conditions, Anatomical
Neurodegenerative Diseases
Neuromuscular Diseases
Spinal Cord Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Frontotemporal Lobar Degeneration
Aphasia
Speech Disorders
Language Disorders
Communication Disorders